Cargando…

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription

To identify genomic alterations contributing to the pathogenesis of high-risk chronic lymphocytic leukemia (CLL) beyond the well-established role of TP53 aberrations, we comprehensively analyzed 75 relapsed/refractory and 71 treatment-naïve high-risk cases from prospective clinical trials by single...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edelmann, Jennifer, Holzmann, Karlheinz, Tausch, Eugen, Saunderson, Emily A., Jebaraj, Billy M. C., Steinbrecher, Daniela, Dolnik, Anna, Blätte, Tamara J., Landau, Dan A., Saub, Jenny, Estenfelder, Sven, Ibach, Stefan, Cymbalista, Florence, Leblond, Veronique, Delmer, Alain, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Goede, Valentin, Bullinger, Lars, Wu, Catherine J., Mertens, Daniel, Ficz, Gabriella, Gribben, John G., Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193490/ https://www.ncbi.nlm.nih.gov/pubmed/31467127 http://dx.doi.org/10.3324/haematol.2019.217307

Ejemplares similares

Lamin B1 regulates somatic mutations and progression of B-cell malignancies
por: Klymenko, T, et al.
Publicado: (2018)

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
por: Bloehdorn, Johannes, et al.
Publicado: (2021)

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
por: Herling, Carmen D., et al.
Publicado: (2020)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
por: Bloehdorn, Johannes, et al.
Publicado: (2021)

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
por: Tausch, Eugen, et al.
Publicado: (2020)

P1411: DUAL EPIGENETIC AND GENETIC EDITING OF PRIMARY HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS
por: Saunderson, E., et al.
Publicado: (2022)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

An shRNA kinase screen identifies regulators of UHRF1 stability and activity in mouse embryonic stem cells
por: Rushton, Michael D., et al.
Publicado: (2022)

Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib
por: Blätte, Tamara J., et al.
Publicado: (2020)

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways
por: Edelmann, Jennifer, et al.
Publicado: (2021)

CRISPR/dCas9 DNA methylation editing is heritable during human hematopoiesis and shapes immune progeny
por: Saunderson, Emily A., et al.
Publicado: (2023)

Telomere Dysfunction in Chronic Lymphocytic Leukemia
por: Jebaraj, Billy Michael Chelliah, et al.
Publicado: (2021)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
por: Freeman, C L, et al.
Publicado: (2016)

Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information
por: Ettrich, T. J., et al.
Publicado: (2019)

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
por: Thiel, V N, et al.
Publicado: (2017)

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors
por: Saunderson, Emily A., et al.
Publicado: (2017)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Targeted therapy in CLL: changing the treatment paradigm
por: Schneider, Christof, et al.
Publicado: (2019)

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
por: Cocciardi, Sibylle, et al.
Publicado: (2019)

Advances in treating chronic lymphocytic leukemia
por: Tausch, Eugen, et al.
Publicado: (2014)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia
por: Zhai, Yanan, et al.
Publicado: (2022)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Rare Germline Variants in ATM Are Associated with Chronic Lymphocytic Leukemia
por: Tiao, Grace, et al.
Publicado: (2017)

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
por: Macintyre, Elizabeth, et al.
Publicado: (2020)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
por: Zapatka, Marc, et al.
Publicado: (2021)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

P614: NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS
por: Qi, Jialei, et al.
Publicado: (2023)

A novel use of random priming-based single-strand library preparation for whole genome sequencing of formalin-fixed paraffin-embedded tissue samples
por: Saunderson, Emily A, et al.
Publicado: (2019)

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair
por: Herzig, Julia K., et al.
Publicado: (2017)

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
por: Kutsch, Nadine, et al.
Publicado: (2020)

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
por: Campo, Elias, et al.
Publicado: (2018)

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia
por: Zajac, Malgorzata, et al.
Publicado: (2017)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ff7716cdhftr5737h1jscsq6ct